HUP0201457A3 - Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations - Google Patents

Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations

Info

Publication number
HUP0201457A3
HUP0201457A3 HU0201457A HUP0201457A HUP0201457A3 HU P0201457 A3 HUP0201457 A3 HU P0201457A3 HU 0201457 A HU0201457 A HU 0201457A HU P0201457 A HUP0201457 A HU P0201457A HU P0201457 A3 HUP0201457 A3 HU P0201457A3
Authority
HU
Hungary
Prior art keywords
preparations
pharmaceutical compositions
crystalline form
compositions containing
eplerenone crystalline
Prior art date
Application number
HU0201457A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pharmacia Corp Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp Chicago filed Critical Pharmacia Corp Chicago
Publication of HUP0201457A2 publication Critical patent/HUP0201457A2/hu
Publication of HUP0201457A3 publication Critical patent/HUP0201457A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Developing Agents For Electrophotography (AREA)
HU0201457A 1999-12-08 2000-12-04 Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations HUP0201457A3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16963999P 1999-12-08 1999-12-08
US16970799P 1999-12-08 1999-12-08
US16968399P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08

Publications (2)

Publication Number Publication Date
HUP0201457A2 HUP0201457A2 (en) 2002-08-28
HUP0201457A3 true HUP0201457A3 (en) 2003-07-28

Family

ID=27558586

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201457A HUP0201457A3 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations

Country Status (18)

Country Link
US (1) US20090149431A1 (enExample)
EP (1) EP1175434A2 (enExample)
JP (2) JP4219105B2 (enExample)
KR (1) KR100584104B1 (enExample)
CN (1) CN100413881C (enExample)
AR (1) AR074665A2 (enExample)
AU (1) AU2041101A (enExample)
BR (1) BR0008054A (enExample)
CA (1) CA2362845A1 (enExample)
CO (1) CO5280205A1 (enExample)
EA (1) EA008449B1 (enExample)
HU (1) HUP0201457A3 (enExample)
IL (2) IL144757A0 (enExample)
MY (1) MY143571A (enExample)
NO (1) NO20013857L (enExample)
NZ (1) NZ513962A (enExample)
PE (1) PE20010918A1 (enExample)
WO (1) WO2001041535A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN104844681B (zh) * 2014-02-13 2016-06-01 合肥久诺医药科技有限公司 一种l晶型依普利酮的精制方法
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
CN113173968B (zh) * 2021-03-19 2026-05-29 江苏苏中药业研究院有限公司 一种依普利酮的纯化方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1997021720A2 (en) * 1995-12-11 1997-06-19 G.D. Searle And Co. Processes for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olifinic double bonds
NZ336004A (en) * 1996-12-11 2001-04-27 G Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base
JP2002538172A (ja) * 1999-03-05 2002-11-12 ジー．ディー．サール エルエルシー 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法

Also Published As

Publication number Publication date
NO20013857D0 (no) 2001-08-08
EP1175434A2 (en) 2002-01-30
EA008449B1 (ru) 2007-06-29
JP4219105B2 (ja) 2009-02-04
JP2003515611A (ja) 2003-05-07
NO20013857L (no) 2001-10-08
WO2001041535A9 (en) 2002-07-04
WO2001041535A2 (en) 2001-06-14
JP2007016043A (ja) 2007-01-25
AR074665A2 (es) 2011-02-02
KR100584104B1 (ko) 2006-05-30
BR0008054A (pt) 2002-03-12
NZ513962A (en) 2004-08-27
CN1433427A (zh) 2003-07-30
CA2362845A1 (en) 2001-06-14
AU2041101A (en) 2001-06-18
PE20010918A1 (es) 2001-09-10
HUP0201457A2 (en) 2002-08-28
US20090149431A1 (en) 2009-06-11
HK1057220A1 (zh) 2004-03-19
CO5280205A1 (es) 2003-05-30
CN100413881C (zh) 2008-08-27
KR20020003192A (ko) 2002-01-10
IL144757A0 (en) 2002-06-30
EA200100869A1 (ru) 2002-04-25
WO2001041535A3 (en) 2001-11-22
MY143571A (en) 2011-05-31
IL144757A (en) 2007-07-24

Similar Documents

Publication Publication Date Title
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0104718A3 (en) Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions
DZ3311A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0201278A3 (en) Pyrazolecarboamide derivative, its preparation, pharmaceutical compositions containing it and its intermediates
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0301404A3 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
IL150346A (en) Benzazole derivatives, their preparation and pharmaceutical compositions containing them
IL148876A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0202255A3 (en) Crystalline 1-methylcarbapenem compounds and pharmaceutical compositions containing them
IL137332A (en) Benzothiadiazoles and derivatives, their preparation and pharmaceutical compositions comprising them
IL147282A0 (en) Novel aminothiazole derivatives, their preparation and pharmaceutical compositions containing them
HUP0201692A2 (en) Streptogramin derivatives, preparation and compositions containing them
HUP0201116A2 (en) Erythromycin derivatives and pharmaceutical compositions containing them and their use
HUP0204154A3 (en) Novel benzothiadiazine derivatives, preparation method and pharmaceutical compositions containing same
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0203627A3 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
HUP0201457A2 (en) Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations
HUP0203032A3 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use
HUP0201443A3 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees